Verona Pharma

156 articles with Verona Pharma

• Verona Pharma to Present at Jefferies Healthcare Conference - May 25, 2022

  5/25/2022

  Verona Pharma plc, announces that Chris Martin, Senior Vice President of Commercial, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 PM ET / 6:30 PM BST.

• Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022

  5/9/2022

  Verona Pharma plc announces the presentation of an abstract demonstrating ensifentrine met all safety objectives in a through QT study at the American Thoracic Society International Conference 2022 taking place on May 13-18.

• Verona Pharma Announces May 2022 Investor Conference Participation

  5/4/2022

  Verona Pharma plc, announces the company will participate in the following conferences in May 2022:

• Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/3/2022

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2022, and provides a corporate update.

• Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update

  4/19/2022

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three months ended March 31, 2022 on Tuesday, May 3, 2022 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m.

• James Brady Joins Verona Pharma as Non-Executive Director

  3/14/2022

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces Mr. James Brady has joined the board as a Non-Executive Director.

• Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

  3/3/2022

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2021, and provides a corporate update.

• Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

  2/17/2022

  Verona Pharma plc announces that it will report its financial results for the fourth quarter and full year ended December 31, 2021 on Thursday, March 3, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

• Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

  1/24/2022

  Verona Pharma plc announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-2 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.

• Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

  1/5/2022

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces enrollment completed in the 48-week subset of the ENHANCE-1 trial in December 2021.

• Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference

  1/4/2022

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference.

• Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac ConductionStudy Supports Ongoing Phase 3 Program and Planned NDA Submission

  12/16/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces ensifentrine met all safety objectives in a thorough QT study designed to evaluate effects, if any, of ensifentrine on cardiac conduction in healthy individuals.

• Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/9/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended September 30, 2021, and provides a corporate update.

• Verona Pharma Announces November 2021 Investor Conference Participation

  11/1/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm.

• Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update

  10/26/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and nine months ended September 30, 2021 on Tuesday, November 9, 2021 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

• Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021

  10/13/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of Phase 2 data demonstrating the positive effect of a pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease at CHEST Annual Meeting 2021 taking place on October 17-20.

• Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021

  9/2/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces an abstract describing a drug-drug interaction study assessing the effect of CYP2C9 inhibitor, fluconazole, on the pharmacokinetics of nebulized ensifentrine in healthy individuals has been published by the European Respiratory Society International Congress 2021.

• Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  8/31/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference.

• Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/5/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended June 30, 2021, and provides a corporate update.

• Verona Pharma Announces August 2021 Virtual Investor Conference Participation

  7/27/2021

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following virtual investor conferences in August 2021